Claims for Patent: 7,049,133

Summary for Patent: 7,049,133

Title:	Regulation of gene expression through manipulation of mRNA splicing and its uses
Abstract:	A cis-acting nucleotide sequence which is capable of rendering the removal of introns from a precursor transcript encoded by a gene, which gene harbors at least one such cis-acting nucleotide sequence, occurring during the production of mRNA of a gene, dependent upon activation of a trans-acting factor. The trans-acting factor is an RNA-activated protein kinase which is capable of phosphorylating the .alpha.-subunit of eukaryotic initiation factor 2. The trans-acting factor is preferably, the RNA-activated protein kinase (PKR). The cis-acting nucleotide sequence can be derived from the 3\' untranslated region of the human tumor necrosis factor .alpha. gene (TNF-.alpha.3\'-UTR) and may comprise the nucleotide sequence as denoted by SEQ ID NO:1 or biologically functional fragments, derivatives, mutants and homologues thereof.
Inventor(s):	Kaempfer; Raymond (Jerusalem, IL), Osman; Farhat (Sakhnin, IL), Jarrous; Nayef (Shefaram, IL), Ben-Asouli; Yitzhak (Kfar Hanagid, IL)
Assignee:	Yissum Research Development Company of the Hebrew University of Jerusalem (Jerusalem, IL)
Application Number:	09/801,371
Patent Claims:	1. A cis-acting nucleotide sequence which is capable of rendering the removal of introns from a precursor transcript encoded by any gene, which gene harbors at least one such cis-acting nucleotide sequence, occurring during the production of mRNA of said gene, dependent upon activation of a trans-acting factor, said trans-acting factor being the RNA-activated protein kinase (PKR) which is capable of phosphorylating the .alpha.-subunit of eukaryotic initiation factor 2, and wherein said cis-acting nucleotide sequence is derived from the 3' untranslated region of the human tumor necrosis factor .alpha. gene (TNF-.alpha.-3'UTR) and consists of a sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2. 2. The cis-acting nucleotide sequence according to claim 1 wherein said cis-acting nucleotide sequence is derived from the 3' untranslated region of the human tumor necrosis factor .alpha. gene (TNF-.alpha.-3'UTR) and consists of the nucleotide sequence denoted by SEQ ID NO:1. 3. The cis-acting nucleotide sequence according to claim 1 wherein said cis-acting nucleotide sequence is derived from the 3' untranslated region of the human tumor necrosis factor .alpha. gene (TNF-.alpha.-3'UTR) and consists of the nucleotide sequence as denoted by SEQ ID NO:2. 4. The cis-acting nucleotide sequence according to claim 3 wherein said gene encodes a protein selected from the group consisting of enzymes, hormones, growth factors, cytokines, structural proteins, industrially applicable proteins, agriculturally applicable proteins, a protein which is a therapeutic product, a protein which is an agricultural product, and a protein which is an industrially applicable product. 5. A DNA construct comprising: a) a gene which contains at least one intron; b) a cis-acting nucleotide sequence which is capable of rendering the removal of introns from a precursor transcript encoded by said gene, which gene includes at least one such cis-acting nucleotide sequence, occurring during the production of mRNA of said gene, dependent upon activation of a trans-acting factor, wherein said trans-acting factor being the RNA-activated protein kinase (PKR) which is capable of phosphorylating the .alpha.-subunit of eukaryotic initiation factor 2, operably linked to said gene; and c) optionally further comprising additional control, promoting and regulatory elements, and wherein said cis-acting nucleotide sequence is derived from the 3' untranslated region of the human tumor necrosis factor .alpha. gene (TNF-.alpha.-3'UTR) and consists of a sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2. 6. The DNA construct according to claim 5 wherein said cis-acting nucleotide sequence is derived from the 3' untranslated region of the human tumor necrosis factor .alpha. gene (TNF-.alpha.-3'UTR) and consists of the nucleotide sequence as denoted by SEQ ID NO:1. 7. The DNA construct according to claim 5 wherein said cis-acting nucleotide sequence is derived from the 3' untranslated region of the human tumor necrosis factor .alpha. gene (TNF-.alpha.-3'UTR) and consists of the nucleotide sequence as denoted by SEQ ID NO:2. 8. A DNA construct according to any one of claims 5, 6 or 7 wherein said control, promoting and regulatory elements are suitable transcription promoters, transcription enhancers and mRNA destabilizing elements. 9. The DNA construct according to claim 5, wherein said gene which contains at least one intron, encodes a protein selected from the group consisting of enzymes, hormones, growth factors, cytokines, structural proteins, industrially applicable proteins, agriculturally applicable proteins, a protein which is a therapeutic product, protein which is an agricultural product, and a protein which is an industrially applicable product. 10. The DNA construct according to claim 9 wherein said nucleotide sequence is contained within an exon of said gene. 11. The DNA construct according to claim 9 wherein said nucleotide sequence is inserted within an intron of said gene. 12. The DNA construct according to claim 10 wherein said gene is the human TNF-.alpha. gene. 13. The DNA construct according to claim 12 being the plasmid pTNF-.alpha., in which said cis-acting nucleotide sequence is contained within an exon of the human TNF-.alpha. gene. 14. The DNA construct according to claim 13 being the plasmid pTNF-.alpha.(3'UTR-.alpha.EP). 15. The DNA construct according to claim 5 wherein said gene is the human TNF-.beta. gene. 16. The DNA construct according to claim 15 in which said cis-acting nucleotide sequence is contained within an exon of the human TNF-.beta. gene. 17. The DNA construct according to claim 16 being the plasmid pTNF-.beta.(3'UTR-.alpha.). 18. The DNA construct according to claim 16 being the plasmid pTNF-.beta.(3'UTR-.alpha.EP). 19. The DNA construct according to claim 11 wherein the DNA construct is pTNF.alpha.(.DELTA.3'UTR)i3EP. 20. A vector comprising the cis-acting nucleotide sequence according to claim 1 or the DNA construct according to claim 5 and a suitable DNA carrier, capable of transfecting a host cell with said cis-acting nucleotide sequence. 21. The vector according to claim 20 optionally further comprising additional expression, control, promoting and regulatory elements operably linked thereto. 22. The vector according to claim 21 wherein said carrier is salmon sperm DNA. 23. The vector according to claim 21 wherein said carrier is viral DNA. 24. A host cell transfected with the DNA construct according to claim 19. 25. A host cell transfected with the vector according to claim 20. 26. A host cell according to claim 24 being a eukaryotic or yeast cell. 27. The host cell according to claim 26 being a mammalian hemopoietic cell, fibroblast, epithelial cell, or lymphocyte. 28. The host cell according to claim 24 wherein said eukaryotic cell is the baby hamster kidney (BHK-21) cell line or the Chinese hamster ovary (CHO) cell line. 29. A composition comprising the expression vector according to claim 20. 30. A method for producing a transfected cell capable of producing a protein comprising a) transfecting a host cell with a DNA construct to give a host cell capable of expressing said protein, wherein said DNA construct comprises a) a gene which contains at least one intron, wherein said gene encodes said protein; b) a cis-acting nucleotide sequence which is capable of rendering the removal of introns from a precursor transcript encoded by said gene, which gene includes at least one such cis-acting nucleotide sequence, occurring during the production of mRNA of said gene, dependent upon activation of a trans-acting factor, wherein said trans-acting factor being the RNA-activated protein kinase (PKR) which is capable of phosphorylating the .alpha.-subunit of eukaryotic initiation factor 2, operably linked to said gene; and c) optionally further comprising additional control, promoting and regulatory elements, and wherein said cis-acting nucleotide sequence is derived from the 3' untranslated region of the human tumor necrosis factor .alpha.gene (TNF-.alpha.-3'UTR) and consists of a sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2; and b) culturing the cell obtained in (a) under culture conditions amenable to express said protein. 31. A method of producing a protein comprising: a) providing host cells transfected with a DNA construct, which are capable of expressing said protwherein said DNA construct comprises a) a gene which contains at least one intron, wherein said gene encodes said protein; b) a cis-acting nucleotide sequence which is capable of rendering the removal of introns from a precursor transcript encoded by said gene, which gene includes at least one such cis-acting nucleotide sequence, occurring during the production of mRNA of said gene, dependent upon activation of a trans-acting factor, wherein said trans-acting factor being the RNA-activated protein kinase (PKR) which is capable of phosphorylating the .alpha.-subunit of eukaryotic initiation factor 2, operably linked to said gene; and c) optionally further comprising additional control, promoting and regulatory elements, and wherein said cis-acting nucleotide sequence is derived from the 3' untranslated region of the human tumor necrosis factor .alpha. gene (TNF-.alpha.-3'UTR) and consists of a sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2; b) culturing the cells provided in (a) under culture conditions amenable to express said protein; and c) isolating said protein from the cell culture obtained in (b). 32. A composition comprising the host cell according to claim 27. 33. A method of producing a protein comprising: a) transfecting a host cell with an expression vector to produce a host cell capable of expressing said protein, wherein said expression vector is selected from the group consisting of (1) a cis-acting nucleotide sequence which is capable of rendering the removal of introns from a precursor transcript encoded by any gene, which gene harbors at least one such cis-acting nucleotide sequence, occurring during the production of mRNA of said gene, dependent upon activation of a trans-acting factor, said trans-acting factor being the RNA-activated protein kinase (PKR) which is capable of phosphorylating the .alpha.-subunit of eukaryotic initiation factor 2, and wherein said cis-acting nucleotide sequence is derived from the 3' untranslated region of the human tumor necrosis factor .alpha. gene (TNF-.alpha.-3'UTR) and consists of a sequence of SEQ ID NO:1 or SEQ ID NO:2; and (2) a DNA construct comprising (A) a gene which contains at least one intron, wherein said gene encodes said protein; (B) a cis-acting nucleotide sequence which is capable of rendering the removal of introns from a precursor transcript encoded by said gene, which gene includes at least one such cis-acting nucleotide sequence, occurring during the production of mRNA of said gene, dependent upon activation of a trans-acting factor, wherein said trans-acting factor being the RNA-activated protein kinase (PKR) which is capable of phosphorylating the .alpha.-subunit of eukaryotic initiation factor 2, operably linked to said gene; and (C) optionally further comprising additional control, promoting and regulatory elements, and wherein said cis-acting nucleotide sequence is derived from the 3' untranslated region of the human tumor necrosis factor .alpha. gene (TNF-.alpha.-3'UTR) and consists of the sequence of SEQ ID NO: 1 or SEQ ID NO: 2 and a suitable DNA carrier; b) culturing the cell obtained in (a) under culture conditions amenable to express said protein; and c) isolating said protein from the cell culture obtained in (b). 34. A method of producing a protein comprising: a) providing host cells transfected with an expression vector to produce a host cell capable of expressing said protein, wherein said expression vector is selected from the group consisting of (1) a cis-acting nucleotide sequence which is capable of rendering the removal of introns from a precursor transcript encoded by any gene, which gene harbors at least one such cis-acting nucleotide sequence, occurring during the production of mRNA of said gene, dependent upon activation of a trans-acting factor, said trans-acting factor being the RNA-activated protein kinase (PKR) which is capable of phosphorylating the .alpha.-subunit of eukaryotic initiation factor 2, and wherein said cis-acting nucleotide sequence is derived from the 3' untranslated region of the human tumor necrosis factor .alpha. gene (TNF-.alpha.-3'UTR) and consists of a sequence of SEQ ID NO:1 or SEQ ID NO:2; and (2) a DNA construct comprising (A) a gene which contains at least one intron, wherein said gene encodes said protein; (B) a cis-acting nucleotide sequence which is capable of rendering the removal of introns from a precursor transcript encoded by said gene, which gene includes at least one such cis-acting nucleotide sequence, occurring during the production of mRNA of said gene, dependent upon activation of a trans-acting factor, wherein said trans-acting factor being the RNA-activated protein kinase (PKR) which is capable of phosphorylating the .alpha.-subunit of eukaryotic initiation factor 2, operably linked to said gene; and (C) optionally further comprising additional control, promoting and regulatory elements, and wherein said cis-acting nucleotide sequence is derived from the 3' untranslated region of the human tumor necrosis factor .alpha. gene (TNF-.alpha.-3'UTR) and consists of the sequence of SEQ ID NO: 1 or SEQ lD NO: 2 and a suitable DNA carrier, b) culturing the cells provided in (a) under culture conditions amenable to express said protein; and c) isolating said protein from the cell culture obtained in (b). 35. A host cell according to claim 25 being a eukaryotic or yeast cell. 36. The host cell according to claim 35 being a mammalian hemopoietic cell, fibroblast, epithelial cell, or lymphocyte. 37. A composition comprising the host cell according to claim 36.

Details for Patent 7,049,133

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2018-09-07
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2018-09-07
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2018-09-07